Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled to Receive First-Line Chemotherapy

A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly... ORIGINAL ARTICLE A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled to Receive First-Line Chemotherapy Jeffrey Crawford, MD,* Francisco Robert, MD,† Michael C. Perry, MD,‡ Chandra Belani, MD,§ and Denise Williams, MD, for the Anemia Prevention in NSCLC Group Results: The study was terminated early because of slow accrual; of Introduction: This study evaluated the safety/efficacy of once- 216 patients enrolled, 211 were evaluable for efficacy. Hb was weekly (QW) epoetin alfa measured by quality of life (QOL), maintained in the immediate group, but it decreased in the delayed hemoglobin (Hb), transfusion incidence, tumor response, and sur- group (12.9 versus 11.6 g/dl final values, respectively). Numerically, vival in patients with chemotherapy-naı¨ve, advanced non-small cell fewer immediate patients required transfusions versus delayed pa- lung cancer (NSCLC). tients. Mean QOL scores, modestly declining in both groups from Methods: Stage IIIB/IV NSCLC patients with Hb 11 to 15 g/dl baseline to final measurement, were not significantly different be- scheduled for at least 8 weeks of first-line chemotherapy were tween groups. Tumor response and median overall survival were randomized to subcutaneously receive 40,000 U of epoetin alfa QW similar between http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled to Receive First-Line Chemotherapy

Williams, Denise
Journal of Thoracic Oncology , Volume 2 (3) – Mar 1, 2007
Download PDF
11 pages

Loading next page...
 
/lp/wolters-kluwer-health/a-randomized-trial-comparing-immediate-versus-delayed-treatment-of-4ZFwJ0JhSu

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e318031cd9a
pmid
17410044
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE A Randomized Trial Comparing Immediate versus Delayed Treatment of Anemia with Once-Weekly Epoetin Alfa in Patients with Non-small Cell Lung Cancer Scheduled to Receive First-Line Chemotherapy Jeffrey Crawford, MD,* Francisco Robert, MD,† Michael C. Perry, MD,‡ Chandra Belani, MD,§ and Denise Williams, MD, for the Anemia Prevention in NSCLC Group Results: The study was terminated early because of slow accrual; of Introduction: This study evaluated the safety/efficacy of once- 216 patients enrolled, 211 were evaluable for efficacy. Hb was weekly (QW) epoetin alfa measured by quality of life (QOL), maintained in the immediate group, but it decreased in the delayed hemoglobin (Hb), transfusion incidence, tumor response, and sur- group (12.9 versus 11.6 g/dl final values, respectively). Numerically, vival in patients with chemotherapy-naı¨ve, advanced non-small cell fewer immediate patients required transfusions versus delayed pa- lung cancer (NSCLC). tients. Mean QOL scores, modestly declining in both groups from Methods: Stage IIIB/IV NSCLC patients with Hb 11 to 15 g/dl baseline to final measurement, were not significantly different be- scheduled for at least 8 weeks of first-line chemotherapy were tween groups. Tumor response and median overall survival were randomized to subcutaneously receive 40,000 U of epoetin alfa QW similar between

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Mar 1, 2007

References

  • Standards of care for anemia management in oncology. Focus on lung carcinoma
    Langer
  • Chemotherapy-induced anemia in adults: incidence and treatment
    Groopman
  • The European Cancer Anaemia Survey (ECAS): a large multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
    Ludwig
  • Current standards and ongoing controversies in the management of locally advanced non-small cell lung cancer
    West
  • Influence of age and comorbidities on the chemotherapeutic management of lung cancer
    Deppermann
  • Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
    Crawford
  • Relationship between hemoglobin levels and quality of life during radiation therapy plus concomitant or sequential chemotherapy in patients with cancer and anemia treated with epoetin alfa
    Shasha
  • Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial
    Bonomi
  • What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592
    Cella
  • Combined modality trials of the Cancer and Leukemia Group B stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity
    Socinski
  • Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
    Rizzo